EU Health Innovation
30 items
Mon, Mar 2, 2026
EMA Backs First Combined COVID-19 and Flu Vaccine
Citizens over 50 may soon receive protection against both flu and COVID-19 with just one shot.
Wed, Mar 4, 2026
EMA Recommends 12 New Medicines for EU Approval
EMA recommends 12 new treatments, including options for rare and paediatric diseases.
Sun, Mar 8, 2026
New EU Guidance for Clinical Trials During Emergencies
New EU rules to ensure quicker, safer clinical trials during health crises.
Wed, Mar 11, 2026
EMA Issues Guidance on Clinical Trials
New EU guidance aims to improve clinical trial conduct during health crises.
Thu, Mar 12, 2026
New EU Reference Labs for Public Health Announced
EU bolstering public health infrastructure by designating specialized reference labs.
Fri, Mar 13, 2026
EDPB & EDPS on harmonising clinical trials
Data protection watchdogs call for safeguards in harmonizing clinical trials.
Sat, Mar 14, 2026
EDPB Supports Biotech Act, Seeks Health Data Safeguards
EU data watchdogs push for strong data protection in biotech research.
Sun, Mar 15, 2026
EU Reference Labs for Public Health - Open Calls
New EU Reference Labs will improve public health and diagnostic testing standards across the EU.
Mon, Mar 16, 2026
EMA Highlights from March PRAC Meeting
Safety update on chikungunya vaccine: risk of aseptic meningitis.
Tue, Mar 17, 2026
Joint Opinion on European Biotech Act Proposal
EU data protection watchdogs want safeguards for health data in Biotech Act.
Wed, Mar 18, 2026
EDPB Supports Biotech Act with Data Safeguards
Stronger data protection requested for health data in EU Biotech Act.
Thu, Mar 19, 2026
EMA Introduces New PRIME Tools for Medicines
EMA enhances PRIME scheme to speed up development of medicines for unmet needs
Fri, Mar 20, 2026
EMA: New Medicines Development Tools
Faster development of innovative EU medicines
Sat, Mar 21, 2026
New PRIME Tools to Accelerate Development of Medicines in the EU
Tue, Mar 24, 2026
EMA: New Tools to Speed Medicine Development
EMA boosts medicine development for unmet needs with new PRIME tools.
Sat, Mar 28, 2026
EMA Restricts Use of Tecovirimat SIGA
Mpox treatment faces restriction due to updated clinical data.
Sun, Mar 29, 2026
EMA Recommends New Lung Cancer Treatment
New lung cancer treatment gets EMA nod, expanding therapy options.
Wed, Apr 1, 2026
EMA: New treatment for relapsed lung cancer approved
New treatment option becomes available for relapsed small cell lung cancer patients.
Thu, Apr 2, 2026
EMA Consults on Reducing Animal Use in Drug Development
New EMA consultation seeks to reduce animal use in preclinical drug research.
Thu, Apr 2, 2026
EMA consults on reducing animal use
EMA consults on methodology to reduce animal testing for new medicines.
Fri, Apr 3, 2026
ECDC Reviews Latvia's Leptospirosis Response
Improving EU preparedness for waterborne disease outbreaks, future responses will be faster.
Fri, Apr 3, 2026
ECDC supports Latvia leptospirosis outbreak review
Improving EU preparedness for leptospirosis and other outbreaks through lessons learned.
Sun, Apr 5, 2026
Lung Cancer: New Treatment Approved in the EU
New treatment offers hope for relapsed lung cancer patients in EU.
Sun, Apr 5, 2026
New Lung Cancer Treatment Recommended by EMA
EMA recommends new lung cancer treatment, offering hope for patients in the EU.
Mon, Apr 6, 2026
EMA Consults on Virtual Control Groups
EMA consults on methodology to reduce animal use in medicine development.
Tue, Apr 7, 2026
ECDC Supports Latvia's Leptospirosis Review
ECDC supports Latvia in improving its response to waterborne disease outbreaks.
Tue, Apr 7, 2026
ECDC Supports Latvia Leptospirosis Review
ECDC helping Latvia improve its response to leptospirosis outbreaks.
Fri, Apr 10, 2026
ECDC & Africa CDC Pilot Mobile App for Surveillance
ECDC partners with Africa CDC on mobile app to boost disease surveillance and response.
Sat, Apr 11, 2026
EMA Consults on Reducing Animal Testing
EMA seeks to reduce animal testing by using virtual control groups in drug development.
Sat, May 2, 2026
EU Agencies Highlight Research Role in Policy-Making
EU policies will be more science-backed, leading to better citizen outcomes.
The European Union is actively enhancing its health innovation landscape by embedding science more deeply into policy and modernizing drug development. The EU Agencies Network on Scientific Advice (EU-ANSA) reinforces the critical role of research in evidence-based policymaking, ensuring better outcomes for citizens. Simultaneously, the European Medicines Agency (EMA) is consulting on innovative approaches like virtual control groups to significantly reduce animal testing in preclinical research, aligning ethical practices with the acceleration of new drug development, such as the recent recommendation for Imdylltra, a new lung cancer treatment.
For citizens, these initiatives mean more effective, scientifically-backed health policies, faster access to new, ethically developed medicines, and strengthened public trust. Businesses benefit from clearer, innovation-friendly regulatory pathways that reduce development costs and time. Looking ahead, the European Centre for Disease Prevention and Control (ECDC) is expanding its reach, piloting a mobile app with Africa CDC for enhanced disease surveillance and supporting Member States like Latvia in reviewing outbreak responses, signaling a push towards more robust, globally coordinated public health protection and rapid responses to health crises.